AndreaBozzo/ceres-open-data-index huggingface dataset:
Mutant loxP vectors for selectable marker recycle and conditional knock-outs

Background
          Gene disruption by targeted integration of transfected constructs becomes increasingly popular for studies of gene function. The chicken B cell line DT40 has been widely used as a model for gene knock-outs due to its high targeted integration activity. Disruption of multiple genes and complementation of the phenotypes is, however, restricted by the number of available selectable marker genes. It is therefore highly desirable to recycle the selectable markers using a site-specific recombination system like Cre/loxP.
        
        
          Results
          We constructed three plasmid vectors (neoR, puroR and bsr), which carry selectable marker genes flanked by two different mutant loxP sites. After stable transfection, the marker genes can be excised from the genome by transient induction of Cre recombinase expression. This excision converts the two mutant loxP sites to an inactive double-mutant loxP. Furthermore we constructed a versatile expression vector to clone cDNA expression cassettes between mutant loxP sites. This vector can also be used to design knock-out constructs in which the floxed marker gene is combined with a cDNA expression cassette. This construct enables gene knock-out and complementation in a single step. Gene expression can subsequently be terminated by the Cre mediated deletion of the cDNA expression cassette. This strategy is powerful for analyzing essential genes, whose disruption brings lethality to the mutant cell.
        
        
          Conclusions
          Mutant loxP vectors have been developed for the recycle of selectable markers and conditional gene knock-out approaches. As the marker and the cDNA expression cassettes are driven by the universally active and evolutionary conserved β-actin promoter, they can be used for the selection of stable transfectants in a wide range of cell lines.
Compound 526354: 3,7,9-Tribromo-1,2,6-trichloro-dibenzo-p-dioxin

Chemical compound data from PubChem database. IUPAC Name: 3,7,9-tribromo-1,2,6-trichlorodibenzo-p-dioxin. Molecular Formula: C12H2Br3Cl3O2. Molecular Weight: 524.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529052: Dihydro-2,4-dimethyl-6-(1-methylethyl)-4H-1,3,5-dithiazine

Chemical compound data from PubChem database. IUPAC Name: 2,4-dimethyl-6-propan-2-yl-1,3,5-dithiazinane. Molecular Formula: C8H17NS2. Molecular Weight: 191.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399514-T1: [Translated] DEVICE FOR MEASURING A DONOR HEART VALVE AND METHOD FOR USE THEREOF

A donor heart valve sizer and method of sizing to increase the quality and yield of, and decrease the expense of fabricating, prosthetic heart valves. The sizer includes an axially-extending sizing portion sized to fit within the lumen of a donor heart valve. The sizing portion may be conical such that a resistance to further insertion is felt when the exterior of the sizing portion contacts the annulus of the valve. A measuring bracket attached to the sizing portion includes a scale aligned with the sizing portion that indicates the final expected valve size based on the position of the fresh donor valve on the sizing portion. The measuring bracket includes regions of acceptable valve sizes, and may also include regions of unacceptable valve sizes. A method of sizing includes utilizing the sizer in the slaughterhouse to reduce the overall number of valves shipped to the valve assembly facility to obtain a particular valve size. The sizer and method are particular useful for sizing xenograft valves, especially porcine aortic valves. The sizing portion may be made of polytetrafluoroethylene, and have an included taper of approximately 4°.
COVID-19 State Profile Report - West Virginia

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
Compound 529078: 1,3-Oxathiane, 2,5-dimethyl

Chemical compound data from PubChem database. IUPAC Name: 2,5-dimethyl-1,3-oxathiane. Molecular Formula: C6H12OS. Molecular Weight: 132.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Supporting Healthy Marriage Evaluation: Eight Sites within the United States, 2003-2013

The Supporting Healthy Marriage (SHM) evaluation was launched in 2003 to develop, to implement, and to test the effectiveness of a program aimed at strengthening low-income couples' marriages as one approach for supporting stable and nurturing family environments and parents' and children's well-being. The evaluation was led by MDRC and was sponsored by the Office of Planning, Research and Evaluation in the Administration for Children and Families, United States Department of Health and Human Services.The SHM program was a voluntary yearlong marriage education program for low-income married couples who had children or were expecting a child. The program provided a series of group workshops based on structured curricula designed to enhance couples' relationships; supplemental activities to build on workshop themes; and family support services to address participation barriers, connect families with other services, and reinforce curricular themes.

The study sample consists of 6,298 couples (12,596 adult sample members) who were expecting a child or had a child under 18 years old at the time of study entry. The sample consists primarily of low-to-modest income, married couples with diverse racial and ethnic backgrounds. In each family, one child was randomly selected to be the focus of any child-related measures gathered in the data collection activities. These children ranged from pre-birth to 14 years old at the time of enrollment in the study. Follow-up interviews were conducted at 12 and 30 months after baseline data collection. More detail is provided in the study documentation.

<b>Units of Response: </b>Low-income married couples with children

<b>Type of Data: </b>Evaluation

<b>Tribal Data: </b>No

<b>COVID-19 Data: </b>No

<b>Periodicity: </b>One-time

<b>SORN: </b>https://www.federalregister.gov/documents/2022/09/19/2022-20139/privacy-act-of-1974-system-of-records

<b>Data Use Agreement: </b>https://www.icpsr.umich.edu/rpxlogin

<b>Data Use Agreement Location: </b>https://www.childandfamilydataarchive.org/cfda/archives/cfda/studies/36852/datadocumentation

<b>Equity Indicators: </b>Sex 

<b>Granularity: </b>Household;Individual

<b>Spatial: </b>United States

<b>Geocoding: </b>Unavailable
Defining signal thresholds in DNA microarrays: exemplary application for invasive cancer

Background
          Genome-wide or application-targeted microarrays containing a subset of genes of interest have become widely used as a research tool with the prospect of diagnostic application. Intrinsic variability of microarray measurements poses a major problem in defining signal thresholds for absent/present or differentially expressed genes. Most strategies have used fold-change threshold values, but variability at low signal intensities may invalidate this approach and it does not provide information about false-positives and false negatives.
        
        
          Results
          We introduce a method to filter false-positives and false-negatives from DNA microarray experiments. This is achieved by evaluating a set of positive and negative controls by receiver operating characteristic (ROC) analysis. As an advantage of this approach, users may define thresholds on the basis of sensitivity and specificity considerations. The area under the ROC curve allows quality control of microarray hybridizations. This method has been applied to custom made microarrays developed for the analysis of invasive melanoma derived tumor cells. It demonstrated that ROC analysis yields a threshold with reduced missclassified genes in microarray experiments.
        
        
          Conclusions
          Provided that a set of appropriate positive and negative controls is included on the microarray, ROC analysis obviates the inherent problem of arbitrarily selecting threshold levels in microarray experiments. The proposed method is applicable to both custom made and commercially available DNA microarrays and will help to improve the reliability of predictions from DNA microarray experiments.
Compound 528923: Benzaldehyde, 2-hydroxy, 3,5-bis-tert.-butyl, oxime, TMS

Chemical compound data from PubChem database. IUPAC Name: 1-(3,5-ditert-butyl-2-trimethylsilyloxyphenyl)-N-trimethylsilyloxymethanimine. Molecular Formula: C21H39NO2Si2. Molecular Weight: 393.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528597: tert-Butyldimethylsilyl 4-((tert-butyldimethylsilyl)oxy)-3,5-dimethoxybenzoate

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 4-[tert-butyl(dimethyl)silyl]oxy-3,5-dimethoxybenzoate. Molecular Formula: C21H38O5Si2. Molecular Weight: 426.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Genetic epidemiology: Juvenile idiopathic arthritis genetics - What's new? What's next?

Studies have established the magnitude of the genetic basis of juvenile idiopathic arthritis (JIA). JIA is a complex genetic condition and the genes that influence susceptibility are actively being sought. A candidate gene approach is being used by several groups. MHC-, cytokine- and T-cell-related genes have all been positively associated with JIA. Here we review some of the latest genetic data, and discuss ways in which JIA genetic research might proceed.
Prevalence of hepatitis B and C markers in high-risk hospitalised patients in Crete: a five-year observational study

Background
          So far the prevalence of viral hepatitis infection in hospitalized patients has not been extensively studied. Therefore we conducted the present five-year observational study to evaluate the prevalence of HBV and HCV infection in high-risk hospitalized patients of Crete, the largest Greek island, Due to the homogeneous population, epidemiological studies can be accurately done.
        
        
          Methods
          The study was carried out in two out of four District General Hospitals, and in the University Hospital of the island. Markers for HBV and HCV were studied and statistically evaluated according to age, sex and geographical area, in a well-defined hospitalized population.
        
        
          Results
          The total prevalence of HBsAg and anti-HCV in the three prefectures during the five-year study is 2.66% and 4.75% respectively. Overall the relative risks were higher in males than females for each hepatitis marker (p < 0.001). Higher prevalence of HBcAb was found in the 41–60 years age group for both sexes (males 36.17%, females 27.38%). Peak HBsAg prevalence was found in the age group of 21–40 and 41–60 years for males (5.4%) and females (3.09%) respectively. Anti-HCV prevalence increases with age reaching the highest prevalence in the age group of 41–60 years for males (7.19%) and in the 61–90 years age group for females (7.16%). For both sexes significant differences between the three locations were identified. For HBsAg a higher prevalence in Heraklion (3.96%) compared to Chania (2.30%, males: p < 0.0001, females: p < 0.05) and Rethymnon (1.45%, males: p < 0.01, females: p < 0.0001) was detected. For HCV a significantly higher prevalence in Heraklion (6.54%) compared to Chania (2.39%, males: p < 0.001, females: p < 0.001) but not in Rethymnon (5.15%, NS). A lower prevalence rate of HBcAb in Heraklion compared to Chania (20.07% versus 23.05%, males: p < 0.001, females: p < 0.001) was found.
        
        
          Conclusions
          These results were possibly overestimated, but nevertheless reflect the situation of the general population within the island as shown by our previous publications in other study groups. Moreover they contribute to the mapping of viral hepatitis prevalence in a geographical area of Southern Europe and may be helpful in planning public health interventional strategies.
Compound 529344: 2-Acetyl-4-isopropenylpyridine

Chemical compound data from PubChem database. IUPAC Name: 1-(4-prop-1-en-2-ylpyridin-2-yl)ethanone. Molecular Formula: C10H11NO. Molecular Weight: 161.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526808: 15-Hydroxy-palmitic acid, methyl ester, tBDMS ether

Chemical compound data from PubChem database. IUPAC Name: methyl 15-[tert-butyl(dimethyl)silyl]oxyhexadecanoate. Molecular Formula: C23H48O3Si. Molecular Weight: 400.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Action Transmittal (AT-OSSP-00-01)

This Action Transmittal (AT) establishes procedures and new criteria by which the Department of Health and Human Services (DHHS) will, on a limited exception basis, consider approving Federal financial participation (FFP) in State automatic data processing (ADP) equipment and services acquisitions, when a State has failed to obtain DHHS' prior written approval in accordance with the requirements of 45 CFR Part 95, Subpart F.

Metadata-only record linking to the original dataset. Open original dataset below.
Publications Using SAMHSA DataNew York City – 5 Boros: Drug-Related Emergency Department Visits, 2004-2011 - All Visits

Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits in New York City (5 boroughs), covering 2004-2011. File includes all drug-related ED visits that are reportable to DAWN without regard for the reason for the visit or the specific drugs involved. It includes visits involving all forms of drug misuse or abuse plus visits resulting from adverse reaction, accidental ingestion, suicide attempts, and visits where patients were seeking detoxification services. These estimates are useful for looking at overall levels of drug involvement in ED visits.File includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol.  Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology.Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
Compound 527294: 1,3-Di-isobutylmesitylene

Chemical compound data from PubChem database. IUPAC Name: 1,3,5-trimethyl-2,4-bis(2-methylpropyl)benzene. Molecular Formula: C17H28. Molecular Weight: 232.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Behavioral Health Barometer: Region 6, Volume 7

Explore state and regional data for HHS Region 6 with this user-friendly behavioral health report. It uses data from the 2021-2022 National Surveys on Drug Use and Health (NSDUH). The topics addressed in this report include substance use, substance use disorders, and mental health. Selected estimates are provided for adolescents aged 12 to 17, underage people aged 12 to 20, adults aged 18 or older, and the general population aged 12 or older. Statistical tests compare population percentages of (1) HHS region versus national estimates, (2) state versus national estimates, and (3) state versus HHS region estimates.
Compound 526253: 1,2,6-Tribromo-3,8-dichloro-dibenzo-p-dioxin

Chemical compound data from PubChem database. IUPAC Name: 1,2,6-tribromo-3,8-dichlorodibenzo-p-dioxin. Molecular Formula: C12H3Br3Cl2O2. Molecular Weight: 489.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Detroit

Data tables consisting of Excel files with estimates, rates, relative standard errors, trends and confidence intervals, covering 2004-2011, for drug-related emergency department visits for the Detroit Metropolitan Statistical Area. Tables are provided for 10 topics (\"analytic categories\") which are defined in the \"Guide to Drug Abuse Warning Trend Tables,\"  a separate document.   Each table includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol. Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology. Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
Patent AT-E401045-T1: [Translated] PRODUCTION PROCESS FOR HEART VALVE PROSTHESIS

The present invention provides a cardiac valve prosthesis comprising a frame (1) and two or more leaflets (2a, 2b) (preferably three) attached to the frame. The leaflets are attached to the frame between posts (8), with a free edge (3a, 3b) which can seal the leaflets together when the valve is closed under back pressure. The leaflets are created in a mathematically defined shape allowing good wash-out of the whole leaflet orifice, including the area close to the frame posts, thereby relieving the problem of thrombus deposition under clinical implant conditions.
Bone loss: Quantitative imaging techniques for assessing bone mass in rheumatoid arthritis

Osteoporosis is associated with low bone mass and microarchitectural deterioration of bone tissue with clinical manifestation of low trauma fractures. Rheumatoid arthritis (RA) is a risk factor due to generalized and articular bone loss. This minireview presents past and current bone mass measurement techniques in RA. These techniques include: plain radiographs, absorptiometry, quantitative computed tomography (QCT) and ultrasound. The most widely used technique is dual x-ray absorptiometry (DXA). RA patients have lower bone mass as compared with normals and substantial bone loss may occur early after the onset of disease. Measurement of bone mineral density (BMD) at the hand using either DXA or ultrasound maybe a useful tool in the management of RA patients.
Patent AT-E401192-T1: [Translated] METHOD AND APPARATUS FOR PRODUCING AN END PART OF A FOOD SAUCE DISPENSING CARTRIDGE

A method and apparatus for constructing a dispensing end portion of a cartridge used to hold and dispense food sauce. A flat end disk is held in a transfer pocket and moved by a disk punch through a die opening smaller in diameter than the disk. The die bends the peripheral portion of the disk into a skirt. The disk punch inserts the disk into the open end of a cartridge body and against a mandrel positioned so that an end portion of the cartridge body extends beyond the skirt. Heat is applied to melt thermoplastic coatings on the disk and cartridge body. A crimping device crimps the end portion oft he cartridge into a flange which is bent against the disk and folds the skirt to form a lip doubled over on the peripheral area of the disk. Thermoplastic coatings bond to weld the flange to the disk with the lip enclosed between them.
Hospital Inpatient Discharges (SPARCS De-Identified): Patient Safety Indicators (PSI) Composite Measures by Hospital: Beginning 2009

The datasets contain hospital discharges counts (numerators, denominators, volume counts), observed, expected and risk-adjusted rates with corresponding 95% confidence intervals for Patient Safety Indicators generated using methodology developed by Agency for Healthcare Research and Quality (AHRQ).

The PSIs are a set of indicators providing information on potential in hospital complications and adverse events following surgeries, procedures, and childbirth. The PSIs were developed by AHRQ after a comprehensive literature review, analysis of ICD-9-CM codes, review by a clinician panel, implementation of risk adjustment, and empirical analyses.

All PSI measures were calculated using Statewide Planning and Research Cooperative System (SPARCS) inpatient data beginning 2009.  US Census data files provided by AHRQ were used to derive denominators for county level (area level) PSI measures.

The mortality, volume and utilization measures PSIs are presented by hospital as rates or counts. Area-level measures are presented by county as rates.
Compound 530515: 2-Chlorobenzoic acid, heptadecyl ester

Chemical compound data from PubChem database. IUPAC Name: heptadecyl 2-chlorobenzoate. Molecular Formula: C24H39ClO2. Molecular Weight: 395.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
CDC STATE System E-Cigarette Legislation - Licensure

1995-2024. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System.  E-Cigarette Legislation—Licensure. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies.  Data are reported on a quarterly basis. Data include information related to requirements, restrictions and penalties associated with holding a retail license to sell e-cigarettes over-the-counter and through vending machines.